Overview

A Study to Test a New Immunotherapy, ABX-001, Alone and in Combination With the Marketed Drug, Pembrolizumab, for the Treatment of Tumors Previously Treated With Other Therapies

Status:
RECRUITING

Trial end date:
2026-10-30

Target enrollment:

Participant gender:

Summary

This is a Phase I/Ib first-in-human, open-label, non-randomized, multicenter, multi-country study to evaluate the safety and tolerability and to establish a recommended Phase 2 dose (RP2D) as well as assess preliminary clinical activity of ABX-001 administered intravenously (IV) alone (Part A) or co-administered with pembrolizumab (Part B) in participants with refractory/relapsed advanced solid tumors.

Phase:

PHASE1

Details

Lead Sponsor:

Abalos Therapeutics GmbH

Treatments:

pembrolizumab